The GHRH(1-29) fragment once approved to assess and treat GH deficiency. Structurally it is GHRH(1-29) analog — the shortest fully active GHRH fragment.

How strong is the evidence for Sermorelin?

PeptideHormone grades Sermorelin at the "Clinical" evidence tier — it is supported by human clinical trials, though still maturing or narrower in scope. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.

What is the half-life of Sermorelin?

The reported circulating half-life of Sermorelin is ~11-12 min.

Sermorelin

The GHRH(1-29) fragment once approved to assess and treat GH deficiency.

AnalogClinicalBased on Growth-hormone-releasing hormoneCompare with GHRH Compare lineage

The shortest fragment of GHRH that still carries the whole instruction, and a clean demonstration that most of a peptide is scaffolding.

Identity

Class: GHRH(1-29) analog — the shortest fully active GHRH fragment
Source: Synthetic analog of GHRH
Receptor: GHRH receptor (GHRHR), a class B GPCR

Key properties

Evidence floorClinicalREF1CLIN1

Molecular weight

≈ 3,358 Da

REF

Half-life (native)

~11-12 min

CLIN

Model dosing

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Sermorelin is GHRH(1-29), the minimal N-terminal fragment that retains full GHRH activity, stimulating pituitary GH release. Formerly approved (as Geref) for assessing and treating growth hormone deficiency, it drives endogenous, feedback-regulated GH rather than supplying it directly; it was later withdrawn from the US market for commercial rather than safety reasons.

Reference notes

GHRH(1-29) is the shortest fragment that keeps full GH-releasing potency — the basis of sermorelin's design.
It was FDA-approved for pediatric GH-deficiency diagnosis and therapy before being commercially withdrawn (~2008).
Its very short half-life produces a brief, physiologic GH pulse.

Common questions

What is Sermorelin?: The GHRH(1-29) fragment once approved to assess and treat GH deficiency. Structurally it is GHRH(1-29) analog — the shortest fully active GHRH fragment.
How does Sermorelin work?: Sermorelin is GHRH(1-29), the minimal N-terminal fragment that retains full GHRH activity, stimulating pituitary GH release. Formerly approved (as Geref) for assessing and treating growth hormone deficiency, it drives endogenous, feedback-regulated GH rather than supplying it directly; it was later withdrawn from the US market for commercial rather than safety reasons.
How strong is the evidence for Sermorelin?: PeptideHormone grades Sermorelin at the "Clinical" evidence tier — it is supported by human clinical trials, though still maturing or narrower in scope. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Sermorelin?: The reported circulating half-life of Sermorelin is ~11-12 min.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? · Clinical interventions in aging, 2006 · PMID 18046908
2.Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency · BioDrugs, 1999 · PMID 18031173
3.Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males · Translational andrology and urology, 2020 · PMID 32257855

External references

Sermorelin in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.